High Pointe Capital Management buys $2,015,881 stake in Biogen Inc (BIIB)

Biogen Inc (BIIB) : High Pointe Capital Management scooped up 830 additional shares in Biogen Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 9, 2016. The investment management firm now holds a total of 6,410 shares of Biogen Inc which is valued at $2,015,881.Biogen Inc makes up approximately 2.83% of High Pointe Capital Management’s portfolio.

Other Hedge Funds, Including , Capital Advisors Incok boosted its stake in BIIB in the latest quarter, The investment management firm added 1,792 additional shares and now holds a total of 21,776 shares of Biogen Inc which is valued at $6,848,334. Biogen Inc makes up approx 1.02% of Capital Advisors Incok’s portfolio. Hap Trading sold out all of its stake in BIIB during the most recent quarter. The investment firm sold 23,940 shares of BIIB which is valued $7,564,082.Mn Services Vermogensbeheer B.v. reduced its stake in BIIB by selling 15 shares or 0.27% in the most recent quarter. The Hedge Fund company now holds 5,555 shares of BIIB which is valued at $1,755,158. Biogen Inc makes up approx 0.35% of Mn Services Vermogensbeheer B.v.’s portfolio.Diam Ltd. reduced its stake in BIIB by selling 13,728 shares or 14.75% in the most recent quarter. The Hedge Fund company now holds 79,347 shares of BIIB which is valued at $25,497,365. Biogen Inc makes up approx 0.37% of Diam Ltd.’s portfolio.Chesley Taft Associates boosted its stake in BIIB in the latest quarter, The investment management firm added 65 additional shares and now holds a total of 6,627 shares of Biogen Inc which is valued at $1,907,118. Biogen Inc makes up approx 0.19% of Chesley Taft Associates’s portfolio.

Biogen Inc opened for trading at $314.17 and hit $314.71 on the upside on Wednesday, eventually ending the session at $313.82, with a gain of 0.13% or 0.4 points. The heightened volatility saw the trading volume jump to 8,52,640 shares. Company has a market cap of $68,764 M.

On the company’s financial health, Biogen Inc reported $5.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.52 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $4.69. The company had revenue of $2894.00 million for the quarter, compared to analysts expectations of $2790.65 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.22 EPS.

Many Wall Street Analysts have commented on Biogen Inc. Biogen Inc was Initiated by Bernstein to “Outperform” on Jun 29, 2016. Biogen Inc was Downgraded by Citigroup to ” Neutral” on Jun 7, 2016.

Biogen Inc. formerly Biogen Idec Inc. is a global biopharmaceutical company. The Company is focused on discovering developing manufacturing and delivering therapies for neurological autoimmune and hematologic disorders. The Company develops manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company’s marketed products include AVONEX PLEGRIDY TECFIDERA TYSABRI FAMPYRA for multiple sclerosis (MS) ALPROLIX for hemophilia B and ELOCTATE for hemophilia A among others. It also collaborates on the development and commercialization of RITUXAN (rituximab) which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is for the treatment of chronic lymphocytic leukemia.

Leave a Reply

Biogen Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Biogen Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.